Evidence map›Paper›PMID 34347914›Full record

ArticleMolecular carcinogenesis2021

A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.

Akihisa Kato, Serina Ng, Amalraj Thangasamy, Haiyong Han, Wendi Zhou, Stephane Raeppel, Michael Fallon, Sushovan Guha, Sudhakar Ammanamanchi

Open access · bronzeAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Akihisa KatoDepartment of Internal Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.
Serina NgDivision of Molecular Medicine, TGen, Phoenix, Arizona, USA.
Amalraj ThangasamyDepartment of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA.
Haiyong HanDivision of Molecular Medicine, TGen, Phoenix, Arizona, USA.
Wendi ZhouDepartment of Pathology, Banner University Medical Center, Phoenix, Arizona, USA.
Stephane RaeppelChemRF Laboratories, Montreal, Quebec, Canada.
Michael FallonDepartment of Internal Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.
Sushovan GuhaDepartment of Internal Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.
Sudhakar AmmanamanchiDepartment of Internal Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.ORCID 0000-0001-6226-9062
University of Arizona · USTranslational Genomics Research Institute · USBanner - University Medical Center Phoenix · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Cancer Genome Atlas (TCGA) of a pancreatic cancer cohort identified high MST1R (RON tyrosine kinase receptor) expression correlated with poor prognosis in human pancreatic cancer. RON expression is null/minimal in normal pancreas but elevates from pan-in lesions through invasive carcinomas. We report using multiple approaches RON directly regulates HIF-1α, a critical driver of genes involved in cancer cell invasion and metastasis. RON and HIF-1α are highly co-expressed in the 101 human PDAC tumors analyzed and RON expression correlated with HIF-1α expression in a subset of PDAC cell lines. knockdown of RON expression in RON positive cells blocked HIF-1α expression, whereas ectopic RON expression in RON null cells induced HIF-1α expression suggesting the direct regulation of HIF-1α by RON kinase receptor. RON regulates HIF-1α through an unreported transcriptional mechanism involving PI3 kinase-mediated AKT phosphorylation and Sp1-dependent HIF-1α promoter activity leading to increased HIF-1α mRNA expression. RON/HIF-1α modulation altered the invasive behavior of PDAC cells. A small-molecule RON kinase inhibitor decreased RON ligand, MSP-induced HIF-1α expression, and invasion of PDAC cells. Immunohistochemical analysis on RON knockdown orthotopic PDAC tumor xenograft confirmed that RON inhibition significantly blocked HIF-1α expression. RON/HIF-1α co-expression also exists in triple-negative breast cancer cells, a tumor type that also lacks molecular therapeutic targets. This is the first report describing RON/HIF-1α axis in any tumor type and is a potential novel therapeutic target.

Indexed as

Up-RegulationAnimalsCarcinoma, Pancreatic DuctalCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitMiceNeoplasm InvasivenessNeoplasm TransplantationPancreatic NeoplasmsPromoter Regions, GeneticReceptor Protein-Tyrosine KinasesSignal TransductionSmall Molecule LibrariesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitReceptor Protein-Tyrosine KinasesRON proteinSmall Molecule Librariesgene expressioninvasionkinasesreceptorsignalingtranscription

Identifiers

PMID34347914
PMCPMC9292374
OpenAlexW3187310386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.